Skip to main content
main-content

Medicine Matters rheumatology

Research news

20-06-2018 | Lupus nephritis | EULAR 2018 | News

Abatacept fails to boost renal response rate in lupus nephritis

The addition of abatacept to standard therapy does not increase the rate of complete renal response among patients with lupus nephritis, phase III study findings show.

20-06-2018 | Juvenile idiopathic arthritis | EULAR 2018 | News

No increase in JIA-associated uveitis risk with etanercept treatment

Patients with juvenile idiopathic arthritis who are treated with etanercept do not have a higher risk for developing uveitis than those given methotrexate, results of a UK cohort study suggest.

20-06-2018 | Systemic lupus erythematosus | EULAR 2018 | News

Encouraging long-term safety findings for belimumab in SLE

Belimumab, a B-lymphocyte stimulator specific inhibitor used for the treatment of systemic lupus erythematosus, has a stable safety profile over 8 years of follow-up, with no new safety signals observed, report researchers.

Video interviews

26-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Trial results on upadacitinib for the treatment of RA

Roy Fleischmann comments on the results of the SELECT-MONOTHERAPY and SELECT-NEXT trials, which provide further evidence for the benefits of upadacitinib in patients with RA (6:18).

Read the accompanying news story

19-06-2018 | Psoriatic arthritis | EULAR 2018 | Video

Expert commentary: Low rates of radiographic progression with secukinumab treatment in PsA patients

Douglas Veale comments on study results showing that secukinumab-treated PsA patients have low rates of radiographic progression regardless of prior TNF inhibitor exposure or concomitant methotrexate treatment (2:45).

Read the accompanying news story

18-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Malignancy and infection risk with JAK inhibitors in RA patients

EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors (5:44).

Read the accompanying news story

15-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Researcher comment: MRI monitoring may not be justified in RA patients in clinical remission

Signe Møller-Bisgaard discusses her findings from the IMAGINE-RA study looking at the effects of adding the target of no osteitis or bone marrow edema on MRI to a conventional treat-to-target regimen in patients with RA (5:10).

Read the accompanying news story

15-06-2018 | Systemic lupus erythematosus | EULAR 2018 | Video

Expert commentary: Promising results with herpes zoster vaccine in SLE patients

Thomas Dörner comments on study results demonstrating that a live attenuated herpes zoster vaccine is well tolerated and provokes an antibody response in patients with SLE (5:14).

Read the accompanying news story here

14-06-2018 | TNF inhibitors | EULAR 2018 | Video

Researcher comment: Role of TNF inhibitors on need for joint replacement in RA

​​​​​​​Samuel Hawley comments on his research findings showing that TNF inhibitors might not play as big a role in the recent reduction in joint replacement procedures in patients with RA as originally thought and that additional factors are likely to be involved. (2:59)

Read the related news story

14-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: COBRA trial 23-year follow-up analysis on mortality rates

Elena Nikiphorou provides her thoughts on the findings of this trial showing a normalization of mortality in patients with rheumatoid arthritis receiving early, intensive treatment (2:41).

Read the accompanying news story here.

image credits